A crystal form A of a TLR7 agonist, and a preparing method and medical uses thereof

The invention relates to a crystal form A of a TLR7 agonist that is 2-butoxy-7-(4-(pyrrolidin-1-yl methyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidine-4-amine (shown as a formula I), and a preparing method and medical uses thereof, and particularly relates to a crystal form A of a TLR7 agonist that is 2-butoxy-7-(4-(pyrrolidin-1-yl methyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidine-4-amine, a preparing method thereof, a crystal composition comprising the crystal form A, a pharmaceutical composition comprising the crystal form A or the crystal composition, and medical uses of the crystal form A, the crystal composition or the pharmaceutical composition. The crystal form A has advantages of high purity, a high crystallization degree, good stability, and easy preparation, and can be used for preparing medicines preventing or treating Toll-like receptor 7 (TLR7) related diseases.